Amgen Agrees to $762M Fine for Drug Misbranding

The biopharmaceutical company Amgen, which is based in Thousand Oaks, Calif., has pleaded guilty to a federal misdemeanor for misbranding its anemia drug and agreed to pay $762 million in fines and penalties, according to a Washington Post report.

Advertisement
Molly Gamble

The company agreed to pay $612 million in a civil settlement, a $14 million criminal forfeiture payment and a $136 million criminal fine, according to the report.

More Articles on Pharmaceutical Settlements:

Johnson & Johnson to Pay $181M Settlement Over Risperdal Marketing
J&J to Pay $2.2B Settlement to End Risperdal Probes
Pfizer Reaches $60M Settlement Over Foreign Bribe Allegations

Building resilient pharmacy procurement in a volatile market

Recommended Whitepaper

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.